Prime Medicine Reports $1.1 Million Revenue in Q2 2025, Continues to Operate at a Loss

Prime Medicine, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $1.1 million, primarily from collaboration revenue with related parties. This marks a significant increase from the same period in 2024, when the company reported no revenue. For the first half of 2025, total revenue reached $2.6 million, compared to $591,000 in the first half of 2024. Despite this revenue growth, the company continues to operate at a loss, with a net loss of $52.6 million for the second quarter, slightly improved from a net loss of $55.3 million in the same quarter of the previous year. The accumulated deficit as of June 30, 2025, stands at $791.7 million.

In terms of operational metrics, Prime Medicine's total operating expenses for the second quarter were $54.5 million, a decrease from $55.7 million in the prior year. Research and development expenses accounted for $41.4 million, down from $43.1 million, reflecting a strategic shift to focus on its in vivo liver franchise. The company has also seen a reduction in personnel-related expenses, attributed to a workforce reduction. General and administrative expenses increased to $13.1 million, driven by higher professional and consultant fees.

The company has made notable strategic developments, including a recent agreement with the Cystic Fibrosis Foundation for up to $24 million in funding to accelerate the development of Prime Editors for cystic fibrosis-related lung disease. Additionally, Prime Medicine is advancing its in vivo liver programs targeting Wilson’s Disease and Alpha-1 Antitrypsin Deficiency, with plans for Investigational New Drug (IND) filings in 2026. The company also reported initial positive data from its Phase 1/2 trial for chronic granulomatous disease, indicating promising results for its candidate PM359.

As of June 30, 2025, Prime Medicine had cash, cash equivalents, and investments totaling $101.8 million, which, along with approximately $138.2 million raised from a recent stock offering in August 2025, is expected to fund operations for at least the next twelve months. The company anticipates continued operating losses as it invests in research and development, with plans to explore additional funding avenues to support its growth strategy. The outlook remains focused on advancing its product candidates and expanding its collaboration agreements, while navigating the challenges typical of early-stage biotechnology firms.